Daraxonrasib has been approved by the Food and Drug Administration to treat stage 4 metastatic pancreatic cancer, according to federal records. Initial studies indicate the drug stretches typical survival times for individuals with advanced forms of the illness from six up to 13 months, introducing an alternative where medical choices were previously scarce.
Early Access Program Brings Treatment to Central Oregon
Seven patients at St. Charles Cancer Institute began taking daraxonrasib through an expanded access program, according to health officials. This program allows patients facing life-threatening conditions to receive prescription medications prior to official federal approval. While the drug is not a cure, health officials note it provides a meaningful extension of life for individuals with limited treatment options.
Medical options for advanced pancreatic cancer have historically been slim. Dr. Christina Fitzmaurice, medical director for research at St. Charles Cancer Institute, highlighted the effect of the new treatment for patients who have exhausted standard care.
“This is the first time in many years that we have a completely new treatment that really makes a noticeable difference in how long those patients live,” Fitzmaurice said. “Especially with metastatic pancreatic cancer, we run out of treatment options pretty quickly. The only thing we can offer is hospice. This medication can extend life by an extra year, which is pretty meaningful.”
Patient Perspective: A New Breath of Life
Seventy-eight-year-old La Pine local John Johnson participates in the early access initiative to receive daraxonrasib treatments. Johnson has had pancreatic cancer for more than a year and had run out of treatment options before joining the program.
“I was on the tail end. This drug coming out, it was like a new breath of life. We will see how long I last – a year, maybe two,” Johnson said. He intends to spend his days tending his garden, working in his shop, and sharing time with his wife, Barb. “All you’ve got to do is keep your chin up and not sit in a chair too much.”
Behind the Scenes of Expanded Access
Staff members across multiple hospital divisions spent months coordinating to obtain early treatment availability for patients ahead of formal FDA authorization. Kat Brookhart, a clinical researcher at St. Charles Cancer Institute, noted the impact of providing early access to patients.
“I love getting to be a part of something this meaningful, which is so important to patients and their families to get precious extra time,” Brookhart said.
Dr. Linyee Chang, executive medical director for St. Charles Cancer Institute, said health care teams remain dedicated to pursuing expanded access programs for emerging therapies. “We want patients in Central Oregon to have access to emerging treatments and medications that can make a powerful difference in their lives,” Chang said. “This is an exciting moment to celebrate and also representative of the kind of work our teams are doing behind the scenes every day to serve our patients.”
Frequently Asked Questions
When was daraxonrasib approved by the FDA?
The Food and Drug Administration approved daraxonrasib on Aug. 26.
How much does daraxonrasib extend life expectancy?
Health authorities report that preliminary testing demonstrates the treatment extends median survival durations from six months to 13 months among patients suffering from late-stage illness.
Who is eligible for early access programs?
Expanded access programs allow patients facing life-threatening conditions to receive prescription medications prior to official federal approval when standard treatment options have been exhausted.
Stay Informed on Local Health News
Subscribe to our newsletter to receive the latest updates on medical advancements, health care access, and community news in Central Oregon.
Worth a look